Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label Clinical Phase 1/2 Study to Assess the Safety and Efficacy of the SpectraCure P18 System and Verteporfin for Injection for the Treatment of Primary Localized Prostate Cancer

NCT06807359 is registered in ClinicalTrials.gov with SpectraCure AB as lead sponsor.

NCT NCT06807359
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06807359 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label Clinical Phase 1/2 Study to Assess the Safety and Efficacy of the SpectraCure P18 System and Verteporfin for Injection for the Treatment of Primary Localized Prostate Cancer
Lead sponsor
SpectraCure AB
Phase
Phase 1/2
Overall status
Recruiting
Start date
January 6, 2025
Completion date
January 31, 2029
Enrollment
43 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer